[go: up one dir, main page]

WO2003106667A3 - REGULATION OF A HUMAN SUBTILASE SERINE PROTEASE - Google Patents

REGULATION OF A HUMAN SUBTILASE SERINE PROTEASE Download PDF

Info

Publication number
WO2003106667A3
WO2003106667A3 PCT/EP2003/006169 EP0306169W WO03106667A3 WO 2003106667 A3 WO2003106667 A3 WO 2003106667A3 EP 0306169 W EP0306169 W EP 0306169W WO 03106667 A3 WO03106667 A3 WO 03106667A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
subtilase
diseases
human
serine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006169
Other languages
French (fr)
Other versions
WO2003106667A2 (en
Inventor
Rainer H Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to AU2003250830A priority Critical patent/AU2003250830A1/en
Publication of WO2003106667A2 publication Critical patent/WO2003106667A2/en
Publication of WO2003106667A3 publication Critical patent/WO2003106667A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des réactifs régulant une sérine protéase de type subtilase humaine et des réactifs se liant à des produits géniques de cette sérine protéase de type subtilase humaine. Ces réactifs peuvent jouer un rôle dans la prévention, l'amélioration ou la correction de dysfonctionnements ou de maladies, notamment mais pas exclusivement du cancer, de troubles endocriniens et hormonaux, du diabète et d'autres troubles métaboliques, de troubles du système nerveux central, de troubles cardiovasculaires, de maladies inflammatoires, de maladies hématologiques, de maladies respiratoires telles que l'asthme et la bronchopneumopathie chronique obstructive, de troubles de la reproduction et de maladies génito-urinaires.The present invention relates to reagents regulating a human subtilase-like serine protease and reagents which bind to gene products of this human subtilase-like serine protease. These reagents can play a role in the prevention, improvement or correction of dysfunctions or diseases, in particular but not exclusively cancer, endocrine and hormonal disorders, diabetes and other metabolic disorders, disorders of the central nervous system , cardiovascular disorders, inflammatory diseases, hematological diseases, respiratory diseases such as asthma and chronic obstructive pulmonary disease, reproductive disorders and genitourinary diseases.

PCT/EP2003/006169 2002-06-12 2003-06-12 Regulation of human subtilase-like serine protease Ceased WO2003106667A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003250830A AU2003250830A1 (en) 2002-06-12 2003-06-12 Regulation of human subtilase-like serine protease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38756902P 2002-06-12 2002-06-12
US60/387,569 2002-06-12
US43119502P 2002-12-06 2002-12-06
US60/431,195 2002-12-06

Publications (2)

Publication Number Publication Date
WO2003106667A2 WO2003106667A2 (en) 2003-12-24
WO2003106667A3 true WO2003106667A3 (en) 2004-02-19

Family

ID=29739950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006169 Ceased WO2003106667A2 (en) 2002-06-12 2003-06-12 Regulation of human subtilase-like serine protease

Country Status (2)

Country Link
AU (1) AU2003250830A1 (en)
WO (1) WO2003106667A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005022187D1 (en) * 2004-05-24 2010-08-19 Novozymes As ENZYMES FOR PHARMACEUTICAL USE
KR20100092450A (en) 2007-12-04 2010-08-20 노보자임스 에이/에스 Protease variants for pharmaceutical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057081A2 (en) * 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
WO2001098340A2 (en) * 2000-06-23 2001-12-27 Bayer Aktiengesellschaft Regulation of human mast cell protease 6-like enzyme
WO2002053719A2 (en) * 2001-01-04 2002-07-11 Incyte Genomics, Inc. Cytoskeleton-associated proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057081A2 (en) * 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
WO2001098340A2 (en) * 2000-06-23 2001-12-27 Bayer Aktiengesellschaft Regulation of human mast cell protease 6-like enzyme
WO2002053719A2 (en) * 2001-01-04 2002-07-11 Incyte Genomics, Inc. Cytoskeleton-associated proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM [online] EMBL; 5 August 1998 (1998-08-05), ANDERSSON ET AL.: "Homo sapiens clone 24649 mRNA sequence", XP002263727, retrieved from EBI Database accession no. AF070591 *
DATABASE EM_MUS [online] EMBL; 23 December 1998 (1998-12-23), ROWEN ET AL.: "Mus jmusculus major histocompability ....", XP002263726, retrieved from EBI Database accession no. AF110520 *
DATABASE SWALL [online] 1 May 1999 (1999-05-01), ROWEN ET AL.: "NG28 (Adult male kidney cDNA, Riken full-length enriched library, clone:0610013D04, full insert)", XP002263725, retrieved from EBI Database accession no. Q9Z1P7 *
NATURE, vol. 409, no. 6821, 8 February 2001 (2001-02-08), pages 685 - 690, XP002207921 *

Also Published As

Publication number Publication date
WO2003106667A2 (en) 2003-12-24
AU2003250830A8 (en) 2003-12-31
AU2003250830A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
NO20054136L (en) Imidazol-4-yl-ethynyl-pyridine derivatives
AU6744501A (en) Regulation of human dopamine-like g protein-coupled receptor
WO2003106667A3 (en) REGULATION OF A HUMAN SUBTILASE SERINE PROTEASE
AU2001280812A1 (en) Gsk3 polypeptides
CA2257136A1 (en) Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
DE69834949D1 (en) DETERMINATION OF THE PREFERENCE POSITION FOR OBSTRUCTIVE LUNG DISEASE BASED ON GENE POLYMORPHISMS OF THE HUMAN AIRWAY TRYPSINE PROTEASE
PT1656458E (en) Human autism susceptibility gene and uses thereof
WO2001094385A3 (en) Human hm74-like g protein coupled receptor
Miller et al. Dietary fat intake and plasma factor VII antigen concentration
WO2006003520A3 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
WO2004005886A3 (en) Kits and methods for assessing cardiovascular health
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
IL180681A0 (en) Pyridine derivatives, their preparation and use
WO2006003523A8 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
IL184538A0 (en) N-hydroxyamide derivatives and use thereof
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2002042435A3 (en) Regulation of human tyrosine phosphatase
ATE374260T1 (en) ASTHMA-ASSOCIATED GENE
WO2002102980A3 (en) Kits and methods for assessing leptin-mediated lipid matabolism
WO2002031160A3 (en) Regulation of human phospholipase a2-like enzyme
WO2001068842A3 (en) Regulation of human p2y-like gpcr protein
ZA200704921B (en) Sulfonyl amino cyclic derivatives and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP